section name header

Pronunciation

des-moe-PRESS-in

Classifications

Therapeutic Classification: hormones

Pharmacologic Classification: antidiuretic hormones

Indications

BEERS REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: <1% absorbed following oral or SL administration; nasal solution 10–20% absorbed; nasal spray 3–4% absorbed.

Distribution: Distribution not fully known.

Metabolism/Excretion: Primarily excreted in urine.

Half-life: PO: 1.5–2.5 hr; SL: 2.8 hr; IV: 75 min ( in renal impairment); Intranasal: 1.8–3.5 hr.

Time/Action Profile

(PO, intranasal = antidiuretic effect; IV = effect on factor VIII activity)

ROUTEONSETPEAKDURATION
PO1 hr4–7 hrunknown
SLunknownunknownunknown
Intranasal1 hr1–5 hr8–20 hr
IVwithin min15–30 min3 hr

†4–24 hr in mild hemophilia A.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, hypertension, hypotension, tachycardia (large IV doses only).

Derm: flushing.

EENT: intranasal: epistaxis, nasal congestion, nasal discomfort, rhinitis, sneezing.

F and E: HYPONATREMIA.

GI: dry mouth, mild abdominal cramps, nausea.

GU: vulval pain.

Local: phlebitis at IV site.

MS: back pain.

Neuro: dizziness, drowsiness, headache, listlessness, SEIZURES.

Resp: dyspnea.

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Primary Nocturnal Enuresis

Diabetes Insipidus

Hemophilia A/von Willebrand's Disease

Nocturia

Availability

(Generic available)

Assessment

Lab Test Considerations: Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

DDAVP, Nocdurna

Canadian Brand Names

Bipazen, DDAVP Melt, Octostim